ClinicalTrials.gg
Active, not recruitingNCT05739383Updated Nov 5, 2026

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

A Phase 3 interventional study of Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL and Placebo in 1.5ml in Primary Prevention of Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 983 sites in 42 countries. Open to participants aged 40 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Prevention

Updated Nov 5, 20266 sites added6 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14,012
Allocation
Randomized
Ages
40 Years to 79 Years
Sex
All
01

Study summary

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.

Read the detailed description

The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the risk of 4P-MACE in adult patients at high risk for their first major adverse cardiovascular event.

Randomized participants will receive study medication (inclisiran or placebo), administered s.c. on Day 1, Day 90, then every 6 months thereafter. This is an event-driven study. Therefore, the study will continue until the required number of clinical events have occurred across both treatment arms, and all participants have a minimum of 3 years of follow-up during the double-blind treatment period.

02

Conditions studied

  • Primary Prevention of Atherosclerotic Cardiovascular Disease

Keywords

  • Inclisiran
  • PCSK9
  • primary prevention
  • cardiovascular disease
  • MACE
  • myocardial infarction
  • stroke
  • LDL-C
  • hyperlipidemia
  • hypercholesterolemia
  • dyslipidemia
  • cholesterol
  • Coronary Artery Disease (CAD)
  • Non-Obstructive Coronary Artery Disease (NOCAD)
  • Coronary Artery Calcium
  • Coronary artery stenosis
  • Coronary angiogram
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 14,012 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At an increased risk for a first MACE (i.e., no prior major ASCVD event), defined as any one of the following:

    1. Evidence of atherosclerotic coronary artery disease (CAD) on computer tomography (CT) or invasive coronary angiogram defined as a coronary artery stenosis ≥20% but \<50% in the left main coronary artery or stenosis ≥20% but \<70% in any other major epicardial coronary artery, or
    2. Coronary artery calcium (CAC) score obtained by CT-scan ≥100 Agatston units, or
    3. High 10-year ASCVD risk ≥20%, or
    4. Intermediate 10-year ASCVD risk 7.5% - \<20% with at least 2 risk-enhancing factors.
  • LDL-C ≥70 mg/dL (≥1.81 mmol/L) but \<190 mg/dL (\<4.91 mmol/L) at the screening visit. If on a background lipid lowering therapy, the dose should be stable for at least 4 weeks prior to the screening visit and the participant should be willing to remain on this background therapy for the entire duration of the study.

Exclusion criteria

Exclusion Criteria:

  • History of major ASCVD event.
  • History of, or planned, ischemia-driven revascularization in a coronary or extracoronary arterial bed prior to randomization
  • Absence of coronary atherosclerosis on a CT angiogram or an invasive coronary angiogram in the 2 years prior to randomization
  • Coronary artery calcium (CAC) score of 0 obtained in the 2 years prior to randomization
  • Active liver disease or hepatic dysfunction
  • Previous, current, or planned treatment with a monoclonal antibody (mAb) directed toward proprotein convertase subtilisin/kexin type 9 (PCSK9) (e.g., evolocumab, alirocumab)
  • Pregnant or nursing (lactating) women
  • Women of unless they are using effective methods of while taking study treatment which includes for 6 months after last study drug administration

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14,012 participants (actual)

Study arms

  • Experimental
    Inclisiran sodium 300mg

    Inclisiran sodium 300 mg in 1.5 mL solution for injection (subcutaneous) in pre-filled syringe. Randomized in a 1:1 ratio with matching placebo

    Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

  • Placebo comparator
    Placebo

    Matching placebo in 1.5ml pre-filled syringe. Randomized in a 1:1 ratio with Inclisiran.

    Drug: Placebo in 1.5ml

Interventions

06

What researchers measure

Primary outcomes

  1. Time to the first occurrence of 4P-MACE

    4-Point-Major Adverse Cardiovascular Events (4P-MACE): composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization.

    Time frame: Time to the first occurrence of 4P-MACE (up to approximately 75 months)

Secondary outcomes

  1. Time to the first occurrence of 3P-MACE

    3-Point-Major Adverse Cardiovascular Events (3P-MACE): composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke)

    Time frame: Time to the first occurrence of 3P-MACE (up to approximately 75 months)

  2. Total number of first or repeated CV events (4P MACE)

    Total 4P-MACE (composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization)

    Time frame: up to 75 months

  3. Total number of first or repeated CV events (3P MACE)

    Total 3P-MACE (composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke)

    Time frame: up to 75 months

  4. Time to occurrence of Cardiovascular death

    CV death is defined as death due to cardiovascular events.

    Time frame: Time to Cardiovascular death (up to 75 months)

  5. Time to occurrence of death due to any reason

    All-cause mortality is death due to any reason.

    Time frame: Time to all-cause mortality (up to 75 months)

07

Study locations

983 sites

Showing the first 100 of 983 sites across 42 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Apr 2029, 73 months after the start.

Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's planned 73 months is above that.

Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2023
First posted
Feb 22, 2023
StartActual
Mar 9, 2023
Primary completionEst.
Apr 16, 2029
CompletionEst.
Apr 16, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 6 sites removed
Show 6 added (3 United States, 1 Brazil, 1 Slovakia, 1 Turkey (Türkiye))
  • Headlands Research Sacramento · Sacramento, United States
  • A and A Research Group Inc · Miami, United States
  • Eminat LLC · Miramar, United States
  • Novartis Investigative Site · Belo Horizonte, Brazil
  • Novartis Investigative Site · Bratislava, Slovakia
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Show 6 removed
  • Clinical Trials Research Sacramento · Sacramento, United States
  • A&A Research Group Inc · Miami, United States
  • FXM Clin Res Miramar LLC · Miramar, United States
  • Synexus Clinical Research · Columbus, United States
  • Novartis Investigative Site · Bratislava, Slovakia
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    6 sites added, 6 sites removed
    Show 6 added (3 United States, 1 Brazil, 1 Slovakia, 1 Turkey (Türkiye))
    • Headlands Research Sacramento · Sacramento, United States
    • A and A Research Group Inc · Miami, United States
    • Eminat LLC · Miramar, United States
    • Novartis Investigative Site · Belo Horizonte, Brazil
    • Novartis Investigative Site · Bratislava, Slovakia
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 6 removed
    • Clinical Trials Research Sacramento · Sacramento, United States
    • A&A Research Group Inc · Miami, United States
    • FXM Clin Res Miramar LLC · Miramar, United States
    • Synexus Clinical Research · Columbus, United States
    • Novartis Investigative Site · Bratislava, Slovakia
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05739383
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Mar 9, 2023
Primary completion
Apr 16, 2029 (estimated)
Completion
Apr 16, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion